Journal of Biological Chemistry · 2006 · 139 citations · 38 references
MedicineImmunologyPathobiologyBone MetabolismCell SignalingSignal TransductionBone FormationBone HealthInflammatory SignalingOsteoclast BiologyOsteoclast FunctionOsteogenesisNf-κb SignalingNitric OxideNitric Oxide ProductionNitric Oxide Synthase RegulationOsteoprotegerin RegulationOsteoprotegerin SignalingPathological Bone ResorptionRankl-mediated Osteoclastogenesis
Nitric oxide (NO) is a multifunctional signaling molecule and a key vasculoprotective and potential osteoprotective factor. NO regulates normal bone remodeling and pathological bone loss in part through affecting the recruitment, formation, and activity of bone-resorbing osteoclasts. Using murine RAW 264.7 and primary bone marrow cells or osteoclasts formed from them by receptor activator of NF-kappaB ligand (RANKL) differentiation, we found that inducible nitric-oxide synthase (iNOS) expression and NO generation were stimulated by interferon (IFN)-gamma or lipopolysaccharide, but not by interleukin-1 or tumor necrosis factor-alpha. Surprisingly, iNOS expression and NO release were also triggered by RANKL. This response was time- and dose-dependent, required NF-kappaB activation and new protein synthesis, and was specifically blocked by the RANKL decoy receptor osteoprotegerin. Preventing RANKL-induced NO (via iNOS-selective inhibition or use of marrow cells from iNOS-/- mice) increased osteoclast formation and bone pit resorption, indicating that such NO normally restrains RANKL-mediated osteoclastogenesis. Additional studies suggested that RANKL-induced NO inhibition of osteoclast formation does not occur via NO activation of a cGMP pathway. Because IFN-beta is also a RANKL-induced autocrine negative feedback inhibitor that limits osteoclastogenesis, we investigated whether IFN-beta is involved in this novel RANKL/iNOS/NO autoregulatory pathway. IFN-beta was induced by RANKL and stimulated iNOS expression and NO release, and a neutralizing antibody to IFN-beta inhibited iNOS/NO elevation in response to RANKL, thereby enhancing osteoclast formation. Thus, RANKL-induced IFN-beta triggers iNOS/NO as an important negative feedback signal during osteoclastogenesis. Specifically targeting this novel autoregulatory pathway may provide new therapeutic approaches to combat various osteolytic bone diseases.
38
Q W Xie, R Whisnant, C F Nathan · The Journal of Experimental Medicine · 1993 · 1.1K citations · Full text
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β
Hiroshi Takayanagi, Sunhwa Kim, Koichi Matsuo et al. · Nature · 2002 · 716 citations
Patricia Collin‐Osdoby, Linda Rothe, Fred Anderson et al. · Journal of Biological Chemistry · 2001 · 400 citations · Full text
Inhibition of NF-κB by S-Nitrosylation
Harvey E. Marshall, Jonathan S. Stamler · Biochemistry · 2001 · 373 citations